Published in Proc Natl Acad Sci U S A on May 01, 1987
Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol Cell Biol (1988) 7.06
K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev (1997) 4.24
Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol (2001) 2.60
Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol (2008) 1.53
The COOH-terminal domain of the Rap1A (Krev-1) protein is isoprenylated and supports transformation by an H-Ras:Rap1A chimeric protein. Mol Cell Biol (1991) 1.52
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One (2011) 1.38
Functional specificity of ras isoforms: so similar but so different. Genes Cancer (2011) 1.30
A Ras by any other name. Mol Cell Biol (2001) 1.07
Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells. J Clin Invest (1992) 0.97
Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas. Br J Cancer (1990) 0.93
Ras p21 in breast tissue: associations with pathology and cellular localisation. Br J Cancer (1992) 0.93
Cell surface molecules of human melanoma. Immunohistochemical analysis of the gp57, GD3, and mel-CSPG antigenic systems. Am J Pathol (1989) 0.91
Ras activation in platelets after stimulation of the thrombin receptor, thromboxane A2 receptor or protein kinase C. Biochem J (1997) 0.90
Ovarian expression of cellular Ki-ras p21 varies with physiological status. Proc Natl Acad Sci U S A (1992) 0.89
Enhanced expression of ras gene products in psoriatic epidermis. Arch Dermatol Res (1988) 0.79
Inhibition of human pancreatic cancer cell (MIA PaCa-2) growth by cholera toxin and 8-chloro-cAMP in vitro. Br J Cancer (1993) 0.78
Time-dependent biological differences in molecular markers of high-grade urothelial cancer over 7 decades (ras proteins, pTEN, uPAR, PAI-1 and MMP-9). Virchows Arch (2012) 0.77
Immunohistochemical analysis of the A4 and AO10 (gp110) cell-surface antigens of human astrocytoma. Am J Pathol (1990) 0.75
Mechanism of activation of a human oncogene. Nature (1982) 12.09
A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature (1982) 11.92
Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family. J Virol (1982) 8.88
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (1982) 6.78
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature (1982) 6.09
Analysis of two divergent rat genomic clones homologous to the transforming gene of Harvey murine sarcoma virus. Proc Natl Acad Sci U S A (1981) 5.51
Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses. Proc Natl Acad Sci U S A (1982) 5.39
Viral oncogenes. Cell (1985) 5.20
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus. Nature (1982) 5.08
T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALB- and Harvey-MSV transforming genes. Nature (1982) 4.54
The action of oncogenes in the cytoplasm and nucleus. Science (1985) 3.62
A cellular oncogene (c-Ki-ras) is amplified, overexpressed, and located within karyotypic abnormalities in mouse adrenocortical tumour cells. Nature (1983) 3.56
Neural tissues express high levels of the cellular src gene product pp60c-src. Mol Cell Biol (1983) 3.27
Neurones express high levels of a structurally modified, activated form of pp60c-src. Nature (1985) 3.21
Three human transforming genes are related to the viral ras oncogenes. Proc Natl Acad Sci U S A (1983) 3.06
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer (1984) 1.97
Markedly elevated levels of an endogenous sarc protein in a hemopoietic precursor cell line. Mol Cell Biol (1981) 1.83
Monoclonal antibodies define differential ras gene expression in malignant and benign colonic diseases. Nature (1984) 1.62
Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A (1985) 1.47
Expression of ras oncogene p21 in prostate cancer. N Engl J Med (1986) 1.35
Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas. Proc Natl Acad Sci U S A (1984) 1.32
ras Oncogene p21 expression is increased in premalignant lesions and high grade bladder carcinoma. J Exp Med (1985) 1.26
Expression of cytokeratins in normal and neoplastic colonic epithelial cells. Implications for cellular differentiation and carcinogenesis. Am J Surg Pathol (1986) 1.15
Immunohistochemical detection of the ras oncogene p21 product in an experimental tumour and in human colorectal neoplasms. Br J Cancer (1985) 1.15
Expression of p21 ras oncoproteins in human cancers. Cancer Res (1986) 1.13
Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum. Br J Cancer (1985) 0.99
In vivo amplification and rearrangement of the c-Ha-ras-1 sequence in a human bladder carcinoma. Gan (1983) 0.81
Human oncogene-related proteins in urine during pregnancy and neoplasia. Clin Lab Med (1986) 0.79
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
The structure of an antigenic determinant in a protein. Cell (1984) 10.85
Tumor necrosis factor (TNF). Science (1985) 8.80
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med (1998) 5.06
Multiple primary lung cancers. J Thorac Cardiovasc Surg (1975) 4.97
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A (1989) 4.66
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Generation of protein-reactive antibodies by short peptides is an event of high frequency: implications for the structural basis of immune recognition. Proc Natl Acad Sci U S A (1983) 4.56
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Chemical synthesis of a polypeptide predicted from nucleotide sequence allows detection of a new retroviral gene product. Nature (1980) 4.35
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Lung cancer and exposure to tobacco smoke in the household. N Engl J Med (1990) 3.23
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem (1990) 2.86
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. Proc Natl Acad Sci U S A (1970) 2.77
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet (1977) 2.69
Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med (1968) 2.62
Detection of antibody to autologous human leukemia cells by immune adherence assays. Proc Natl Acad Sci U S A (1977) 2.59
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. Cancer Res (1966) 2.57
Screening for early lung cancer. Results of the Memorial Sloan-Kettering study in New York. Chest (1984) 2.56
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Thymus cells of radiation-chimeras: TL phenotype, sensitivity to guinea-pig serum, and origin from donor cells. Nature (1965) 2.54
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A (1999) 2.53
Leukemia-associated transplantation antigens related to murine leukemia virus. The X.1 system: immune response controlled by a locus linked to H-2. J Exp Med (1973) 2.52
Serologically demonstrable alloantigens of mouse epidermal cells. J Exp Med (1972) 2.48
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A (1994) 2.44
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
Lymphocyte stimulation: a rapid multiparameter analysis. Proc Natl Acad Sci U S A (1976) 2.37
Horizontal transmission of feline leukaemia virus. Nature (1973) 2.34
Group-specific viral antigens in the milk and tissues of mice naturally infected with mammary tumor virus or Gross leukemia virus. Virology (1968) 2.26
Humoral immune responses of cancer patients against "Cancer-Testis" antigen NY-ESO-1: correlation with clinical events. Int J Cancer (1999) 2.26
Simultaneous staining of ribonucleic and deoxyribonucleic acids in unfixed cells using acridine orange in a flow cytofluorometric system. J Histochem Cytochem (1977) 2.23
Common properties of the oncogenic RNA viruses (oncornaviruses). Virology (1970) 2.20
Wild-type Gross leukemia virus. I. Soluble antigen (GSA) in the plasma and tissues of infected mice. J Natl Cancer Inst (1968) 2.17
The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science (1988) 2.16
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst (1977) 2.15
Age-related changes in cell surface antigens of preleukemic AKR thymocytes. J Exp Med (1976) 2.15
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A (1985) 2.14
Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem (1999) 2.14
Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? Nature (1984) 2.14
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Isoantigens of the H-2 and Tla loci of the mouse: interactions affecting their representation on thymocytes. J Exp Med (1968) 2.11
Cell surface antigens of human renal cancer defined by mouse monoclonal antibodies: identification of tissue-specific kidney glycoproteins. Proc Natl Acad Sci U S A (1981) 2.09
The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest (1992) 2.09
Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol (1991) 2.05
Cloning of a brain protein identified by autoantibodies from a patient with paraneoplastic cerebellar degeneration. Proc Natl Acad Sci U S A (1987) 2.05
New cell cycle compartments identified by multiparameter flow cytometry. Cytometry (1980) 2.03
Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1984) 2.02
Serological identification of embryonic neural proteins as highly immunogenic tumor antigens in small cell lung cancer. Proc Natl Acad Sci U S A (2000) 2.02
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med (1985) 2.00
Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc Natl Acad Sci U S A (1988) 1.97